Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited.

Methods

We used a genetic mouse model of PD1 deletion (MRL/Pdcd1^-/-) along with a novel drug-treated ICI myocarditis mouse model to recapitulate the disease phenotype. We performed single-cell RNA-sequencing, single-cell T-cell receptor sequencing, and cellular indexing of transcriptomes and epitopes on immune cells isolated from MRL and MRL/Pdcd1^-/- mice at serial time points. We assessed the impact of macrophage deletion in MRL/Pdcd1<

SUBMITTER: Huang YV 

PROVIDER: S-EPMC11867805 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature